Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials

Dramatically rising costs in drug development are in large part because of the high failure rates in clinical phase trials. The poor correlation of animal studies to human toxicity and efficacy have led many developers to question the value of requiring animal studies in determining which drugs shou...

Descripción completa

Detalles Bibliográficos
Autor principal: Van Norman, Gail A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
TRANSLATIONAL TOOLBOX
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185927/
https://www.ncbi.nlm.nih.gov/pubmed/32363250
http://dx.doi.org/10.1016/j.jacbts.2020.03.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185927/
https://www.ncbi.nlm.nih.gov/pubmed/32363250
http://dx.doi.org/10.1016/j.jacbts.2020.03.010

Ejemplares similares